Advertisement

Meyka AI - Contribute to AI-powered stock and crypto research platform
Meyka Stock Market API - Real-time financial data and AI insights for developers
Advertise on Meyka - Reach investors and traders across 10 global markets
Loading...

Novacyt S.A.

NVYTFPNK
Healthcare
Medical - Devices
$0.48
$0.00(0.00%)
U.S. Market opens in 14h 45m

Novacyt S.A. Fundamental Analysis

Novacyt S.A. (NVYTF) shows moderate financial fundamentals with a PE ratio of -0.67, profit margin of -1.20%, and ROE of -73.00%. The company generates $0.0B in annual revenue with strong year-over-year growth of 69.53%.

Key Strengths

Cash Position96.21%
PEG Ratio-0.04
Current Ratio5.94

Areas of Concern

ROE-73.00%
Operating Margin-56.62%
We analyze NVYTF's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -115.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-115.3/100

We analyze NVYTF's fundamental strength across five key dimensions:

Efficiency Score

Weak

NVYTF struggles to generate sufficient returns from assets.

ROA > 10%
-42.97%

Valuation Score

Excellent

NVYTF trades at attractive valuation levels.

PE < 25
-0.67
PEG Ratio < 2
-0.04

Growth Score

Moderate

NVYTF shows steady but slowing expansion.

Revenue Growth > 5%
69.53%
EPS Growth > 10%
-47.50%

Financial Health Score

Excellent

NVYTF maintains a strong and stable balance sheet.

Debt/Equity < 1
0.23
Current Ratio > 1
5.94

Profitability Score

Weak

NVYTF struggles to sustain strong margins.

ROE > 15%
-7299.55%
Net Margin ≥ 15%
-1.20%
Positive Free Cash Flow
No

Key Financial Metrics

Is NVYTF Expensive or Cheap?

P/E Ratio

NVYTF trades at -0.67 times earnings. This suggests potential undervaluation.

-0.67

PEG Ratio

When adjusting for growth, NVYTF's PEG of -0.04 indicates potential undervaluation.

-0.04

Price to Book

The market values Novacyt S.A. at 0.45 times its book value. This may indicate undervaluation.

0.45

EV/EBITDA

Enterprise value stands at -1.70 times EBITDA. This is generally considered low.

-1.70

How Well Does NVYTF Make Money?

Net Profit Margin

For every $100 in sales, Novacyt S.A. keeps $-1.20 as profit after all expenses.

-1.20%

Operating Margin

Core operations generate -56.62 in profit for every $100 in revenue, before interest and taxes.

-56.62%

ROE

Management delivers $-73.00 in profit for every $100 of shareholder equity.

-73.00%

ROA

Novacyt S.A. generates $-42.97 in profit for every $100 in assets, demonstrating efficient asset deployment.

-42.97%

Following the Money - Real Cash Generation

Operating Cash Flow

Novacyt S.A. generates limited operating cash flow of $-5.91M, signaling weaker underlying cash strength.

$-5.91M

Free Cash Flow

Novacyt S.A. generates weak or negative free cash flow of $-6.64M, restricting financial flexibility.

$-6.64M

FCF Per Share

Each share generates $-0.09 in free cash annually.

$-0.09

FCF Yield

NVYTF converts -26.56% of its market value into free cash.

-26.56%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.67

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.04

vs 25 benchmark

P/B Ratio

Price to book value ratio

0.45

vs 25 benchmark

P/S Ratio

Price to sales ratio

0.81

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.23

vs 25 benchmark

Current Ratio

Current assets to current liabilities

5.94

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-0.73

vs 25 benchmark

ROA

Return on assets percentage

-0.43

vs 25 benchmark

ROCE

Return on capital employed

-0.22

vs 25 benchmark

How NVYTF Stacks Against Its Sector Peers

MetricNVYTF ValueSector AveragePerformance
P/E Ratio-0.6729.45 Better (Cheaper)
ROE-73.00%779.00% Weak
Net Margin-119.81%-24930.00% (disorted) Weak
Debt/Equity0.230.26 Neutral
Current Ratio5.944.65 Strong Liquidity
ROA-42.97%-19333.00% (disorted) Weak

NVYTF outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Novacyt S.A.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

13.74%

Industry Style: Defensive, Growth, Innovation

High Growth

EPS CAGR

-711.09%

Industry Style: Defensive, Growth, Innovation

Declining

FCF CAGR

-546.24%

Industry Style: Defensive, Growth, Innovation

Declining

Fundamental Analysis FAQ